Conducting a
Benefit Investigation (BI)

Although the anti-VEGF agent EYLEA is covered by most payers, it's important that you understand patient-specific insurance benefits and plan restrictions. Before a patient starts EYLEA treatment, it is recommended that you conduct a BI by completing and submitting an EYLEA4U® Enrollment Form.

Once you complete the EYLEA4U Enrollment Form and EYLEA4U confirms patient insurance benefits via the BI, you’ll find a wide array of support and solutions available.

EYLEA4U® logo.

The Enrollment Form

Allows EYLEA4U to verify insurance coverage and determine program eligibility based on the support requested. The following support is available:

  • BI
  • Copay Assistance
  • Claims Assistance
  • Appeals Support
  • Prior Authorization (PA) Assistance
  • Patient Assistance Program (PAP)
EYLEA® (aflibercept) Injection enrollment form icon.

Submit the completed form by fax to 1-888-335-3264 or complete electronically via the EYLEA4U e-Portal*

Visit the portal

*A completed and patient-signed form must be retained on file at the office for submissions entered via the e-Portal.

EYLEA4U Enrollment Form

Complete the EYLEA4U Enrollment Form to begin the process of helping your patients receive assistance.
Refer to the EYLEA4U Enrollment and BI Results Guide to learn more about filling out the appropriate forms.

{{DownloadFormModel.OutputFileName}}.zip  {{DownloadFormModel.DownloadSize}} MB
Support for the reimbursement process.
EYLEA® (aflibercept) Injection benefits investigation results form.

Understanding the
BI results

EYLEA4U support includes a thorough BI that—within 2 business days—summarizes your patient's coverage, PA requirements, cost responsibility, and any additional coverage information.

This comprehensive report is communicated by fax or via the EYLEA4U e-Portal within 2 business days of enrollment submission. Learn how to understand these BI results by downloading the helpful guide below.

PA Assistance

Some insurance plans may require a PA before considering coverage for EYLEA. If required, our Reimbursement Specialists at EYLEA4U can review and provide information on the PA requirements for a specific payer.

Call EYLEA4U at 1-855-EYLEA4U (1-855-395-3248), Option 4, Monday-Friday 9 AM-8 PM Eastern Time.

Claims and appeals support

EYLEA4U is available to support your office with claims and appeals assistance. If you have questions or need information to prepare a claim, we’re here to help. We can also check the status of an existing claim with the patient’s insurer. Simply contact one of our knowledgeable Reimbursement Specialists.

If you received an underpaid or denied claim for EYLEA, we can provide you with information on how to resolve the issue. We can also research and explain the insurer’s appeal process in detail.

EYLEA4U® logo

We have one-on-one reimbursement solutions and are here to help you through the entire reimbursement process

In addition to the BI, EYLEA4U Reimbursement Specialists can help with the following:

Claims Assistance:

  • Address questions on claims preparation
  • Review the status of an EYLEA claim with the patient's insurer

Appeals Assistance:

  • Provide information for resolving underpaid or denied claims or PAs for EYLEA
  • Explain the insurer's appeals process

Resource Center

Visit this helpful library to find enrollment forms, patient pamphlets, and more.

EYLEA® (aflibercept) Injection documents icon.
EYLEA® (aflibercept) Injection ICD-10 code finder.

ICD-10 Code Finder

Use the interactive code finder to quickly find the current ICD-10 codes for

Patient support for EYLEA® (aflibercept) Injection.
Patient Support

We're committed to help ensure
your eligible patients have
access to EYLEA.

Find out more
Product support for EYLEA® (aflibercept) Injection.
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

Learn how it works
EYLEA news, events, and more.

Get the information you
and your patients need
about EYLEA.

See resources
See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.